Company / Cash & Equivalents
Foghorn Therapeutics Inc. Cash & Equivalents History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$80.9M
FY2025
5-year range
$52.2M / $92.8M
FY2021-FY2025
Trend
+45.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 6 years, ranging from $52M in FY2022 to $93M in FY2021.
Based on SEC 10-K filings.
$81M in FY2025 with a 5-year CAGR of -2.7%.
Remained stable around $81M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +15.7%
- 5-Year CAGR
- -2.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -2.7%, indicating a declining trend.
- In FY2025, cash & equivalents increased 45.8% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
- Lowest cash & equivalents in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -1.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $80.9M | +45.8% |
| FY2024 | $55.5M | -31.0% |
| FY2023 | $80.3M | +53.9% |
| FY2022 | $52.2M | -43.7% |
| FY2021 | $92.8M | +0.0% |
| FY2020 | $92.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026